Autopsy report · NCT00441701
Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)
Cause of deathNo reason given
Life of this trial
- Registered 3 months after it had already started.
- Ran for about 1 year 10 months before it stopped.
- 99 participants enrolled.
- Results were posted on the registry 6 years after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Industry
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Navarixin 1 mg; Navarixin 10 mg; Placebo to match navarixin; Rescue medication
- Participants
- 99
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.